Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

The paclitaxel-coated device, already approved in Europe and other parts of the world, will be tested on more than 1,200 patients for a new international trial. If the study is a success, Medtronic hopes to gain regulatory approval in the United States and Japan. 

See What’s New:

"We vehemently refute all their manufactured allegations, and we will vigorously defend our position," CEO Rich Whitney, MBA, said Wednesday. 

Less alarm fatigue in overworked pediatric nurses means more time for imperiled pediatric patients. 

Surgeons purportedly labeled the interventional rad the "Boston Butcher" after he allegedly flubbed several procedures, with 1 leading to a patient's death. 

The ACR's Neiman Policy Institute believes residency slot increases and reductions in inappropriate imaging orders are needed to counter these trends. 

“When healthcare prices are hidden, large corporate entities like hospitals and insurance companies benefit," the White House said.  

The Lexington, Massachusetts, company will outfit multiple federal facilities with its imaging solution beginning in Q1. 

We have seen the future of pain management, and it is in automated assessments aided by AI.